Publications by authors named "F Duffaud"
Objectives: Primary ovarian leiomyosarcomas are exceptionally rare, constituting less than 1% of ovarian tumors, and they typically have a poor prognosis. The available data on the management of these tumors are sparse, with limited publications mainly comprising small retrospective series that include multiple histologic types. The aim is to evaluate the clinical, surgical, pathologic characteristics and clinical outcome of patient affected by primary ovarian leiomyosarcomas.
View Article and Find Full Text PDFA French Multicenter Real-Life Study on the Biological and Clinical Parameters Associated With Response to Immune Checkpoint Inhibitors (ICIs) in Second-Line Treatment of Advanced Urothelial Carcinoma: Impact of Antibiotics Administration at the Time of ICIs Initiation.
Clin Genitourin Cancer
February 2025
Background: After failure of first-line chemotherapy, standard of care for advanced urothelial cancer (aUC) is immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 pathway. Several prognostic models (Bajorin and Bellmunt scores) have been evaluated, but only in the context of chemotherapy.
Objective: To study whether the variables in these scores and new emerging clinical and biological criteria have an impact on the probability of objective response in aUC treated with ICIs in 2nd-line setting and beyond.
Article Synopsis
- The treatment of advanced chondrosarcoma, which often doesn't respond well to standard chemotherapy, is currently being explored through targeted therapies aimed at specific genetic mutations and signaling pathways.
- New strategies include utilizing IDH inhibitors for tumors with IDH mutations, hedgehog pathway inhibitors, and various forms of immunotherapy, all facing challenges but showing potential for effectiveness.
- There's a strong emphasis on using personalized, multi-omics approaches to create combination therapies that can better address the heterogeneous nature of chondrosarcoma and possibly improve treatment outcomes.
Background: While the use of chemotherapy near the end of life (EOL) has been identified as a relevant criterion for assessing quality of cancer care and has been estimated as non-beneficial, a trend of aggressiveness in cancer care during the last period of life remains. Both patients' sociodemographic characteristics and physicians' practice setting are associated with this use. The role of patients' psychosocial characteristics has however been understudied.
View Article and Find Full Text PDF